Bristol-Myers Squibb-Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note

Core Viewpoint - Bristol Myers Squibb (BMY) is experiencing notable stock performance and is set to report earnings, with significant year-over-year changes anticipated in both earnings per share (EPS) and revenue [2][3]. Company Performance - BMY closed at $60.08, reflecting a +0.3% change from the previous session, while the S&P 500 gained 1.08% [1] - The stock has increased by 10.05% over the past month, outperforming the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26% [1] Earnings Forecast - The upcoming earnings report on April 24, 2025, is expected to show an EPS of$ 1.55, representing a 135.23% increase from the same quarter last year [2] - Revenue is forecasted at $10.69 billion, which is a decrease of 9.94% from the prior-year quarter [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of$ 6.75 per share and revenue of $45.59 billion, indicating year-over-year changes of +486.96% and -5.6%, respectively [3] Analyst Estimates - Recent adjustments to analyst estimates for BMY reflect short-term business trends, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks BMY as 3 (Hold) [6] Valuation Metrics - BMY is trading with a Forward P/E ratio of 8.88, which is below the industry average of 19.17 [7] - The company has a PEG ratio of 2.22, compared to the industry average PEG ratio of 1.55 [7] Industry Context - BMY operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [8]